How is the pharmaceutical value chain faring financially? Who are the biggest winners and losers? Every two years, Kearney analyzes pharmaceutical profit pools to answer those questions. Our analysis follows a drug across the value chain, from concept to patient.
Read the December 11th issue of Chain Drug Review, which includes a special section commemorating the 90th anniversary of the founding of the National Association of Chain Drug Stores. The 56-page section is presented by CDR, Drug Store News and the Emerson Group.
As the start of a new year approaches, long-standing trends are raising the stakes for big pharmacy operators and other companies with the ambition to re-engineer a health care system plagued by chronic issues of access, quality and cost.
This is an especially special holiday season for participants in and advocates of chain drug retailing in America. Reason? The season celebrates and pauses to recall the 90th anniversary of the National Association of Chain Drug Stores.
Dinakaran (Dina) Balasubramanian, head of commercial strategy and insights for biologics at Dr. Reddy’s Laboratories, spoke with Chain Drug Review about his role at the drug maker and how specialty generic drugs and biosimilars are fueling growth for it.
